We seek strategic commercial partnerships to marry the formidable science base of the Institute with the capabilities of our commercial partners to add value or derisk technologies for mutual benefit.

Watch this video to find out more from our scientists, collaborators and investors about how Science at Scale is helping to transform the way that we innovate at Sanger.

Innovation Partnerships with the Sanger Institute

We believe that convergence and coordination both across technology fields, and the public the private and the charitable sectors are key to driving the next wave of genomic innovation. This is why, Sanger’s scientists work in collaboration with a range of industry partners and investors to deliver innovative healthcare solutions to some of society’s most challenging problems such as global tracking and prevention of the spread of infectious diseases and making new cancer medicines.

We have already partnered with a wide range of commercial organisations, large and small, ranging from investors and the biotech or pharmaceutical companies to reagents and service providers.


Would like to explore ways to collaborate with us? Contact us at


Open Targets

Open Targets is an innovative public-private partnership, of which the Sanger Institute is a founding member. The partnership generates experimental evidence to support causal links between drug targets and diseases, and exploits human genetics and genomics data for systematic drug target identification and prioritisation within its informatics platforms. Open Targets is working to create an R&D framework that applies to a wide range of human diseases, and is committed to sharing its data openly with the scientific community.

CRISPR screen collaboration with AstraZeneca

The Sanger Institute and AstraZeneca are pulling reources in a collaborative effort which encompasses a suite of individual projects over several years and could see applications in fields as diverse as regenerative medicine, cancer, inflammation or metabolic diseases. The Institute brings its expertise in genome editing and gRNA libraries developed by Dr Kosuke Yusa while AstraZeneca provides access to its compounds, expertise and cell lines. Findings arising from this common effort will be shared with the worldwide research community for them to build on.

Catalogue of Somatic Mutations in Cancer

The Sanger Institute has implemented a licensing step access by commercial parties to its curated catalogue of somatic cancer mutations database, COSMIC (Catalogue of Somatic Mutations in Cancer), in an effort to sustain its development in the context of increasing cancer genomics data. All income generated by this activity, as well as from sponsored database research and development, is used to grow the database as a key public resource.